Video description: GLP-1 facial fat loss, masseter Botox and topical rapamycin
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedThe description attributes to the episode MRI data of about 7% midfacial volume loss per 10 kg lost on GLP-1 drugs, mixed human and consistent animal data on jawbone thinning after repeated masseter Botox, and a proposed topical rapamycin effect on aged skin fibroblasts. [1]
The description attributes MRI data to the episode showing roughly 7% midfacial volume loss per 10 kg of weight lost on GLP-1 drugs, mainly from cheek fat pads. [1]
The description says repeated masseter Botox can thin the mandibular bone, especially in postmenopausal women, with mixed human and consistent animal data. [1]
The description presents topical rapamycin as possibly shifting aged skin fibroblasts toward a younger phenotype, an emerging frontier rather than an established human benefit. [1]
GLP-1 facial fat loss in MRI data
According to the description, the episode presents MRI data showing that GLP-1 drugs reduce facial fat in a distinctive way: roughly 7% midfacial volume loss for every 10 kg of weight lost, mainly from superficial and deep cheek fat pads, which the description links to "Ozempic face." The description also says collagen biostimulators such as Sculptra and Radiesse may preserve or restore facial volume during rapid weight loss, citing 20+ years and 200+ peer-reviewed papers on their collagen-remodeling effects. These are attributed to the description and creator, not verified here. [1]
Masseter Botox and jawbone thinning evidence
The description states that repeated masseter Botox can thin the mandibular bone, especially in postmenopausal women. It characterizes the evidence as mixed in humans but consistent in animal data, and says caution is warranted with aggressive long-term use. The description does not report sample sizes, follow-up periods or effect sizes for these observations. [1]
Proposed topical rapamycin skin rejuvenation
The description says topical rapamycin, called a "rapalog," may reset the fibroblast mTOR cycle, shifting aged, bloated skin cells toward a younger, spindle-shaped phenotype; the chapter title mentions resetting fibroblasts to a 20-year-old state. This is presented as an emerging frontier in cellular skin rejuvenation, not as an established human benefit. The description also calls the exosome and research-peptide markets largely unregulated, noting that source, purity, shelf life and donor quality matter and that lyophilized "exosome" skincare is often just protein fragments. [1]
Context & limits
This is based only on the supplied video description; the video and transcript were not reviewed. All findings, study details and safety-related statements are attributed to the description and creator and were not independently verified. The description does not report sample sizes, follow-up or effect sizes for most claims, and proposed mechanisms such as topical rapamycin resetting fibroblasts are not established human benefits.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
roughly 7% midfacial volume loss for every
Repeated masseter Botox can thin the mandibular
shifting aged, bloated skin cells toward a
About this video
Creator description · original textText language: English
RobertLufkinMD · 45 min · Source published: 2026-09-28
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.